Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients

Filiz Güladalı1, Ceyda Anar2, Melih Büyükşirin3, Merve Aytık Türk4, Günsel Balci5, Mine Gayaf6, Murat Akyol4, İbrahim Onur Aheç7, Gülru Polat4, Gülistan Karadeniz8, Ayşu Ayranç8, Fatma Demirci Üçsular9, Kadri Murat Erdoğan10, Yaşar Kutbay7, Şener Arıkan7, Özgür Batum7, Berna Kömürcuoğlu7, Sinem Ermin7

1Department of Chest Disease, University of Health Sciences Doctor Suat Seren Chest Diseases and Thoracic Surgery Education and Research Hospital, Izmir, Turkey
2Department of Chest Disease, Izmir Katip Celebi University Ataturk Education and Research Hospital, Izmir, Turkey
3Department of Chest Disease, Izmir Bakircay University Cigli Education and Research Hospital, Izmir, Turkey
4Department of Medical Genetics, Izmir Tepecik Education and Research Hospital, Izmir, Turkey
5Department of Medical Oncology, Izmir Bakircay University Cigli Education and Research Hospital, Izmir, Turkey

Cite as: Güladalı F, Anar C, Büyükşirin M, Aytık Türk M, Balci G, Gayaf M, Aheç O, Polat G, Karadeniz G, Ayranç A, Demirci Üçsular F, Erdoğan KM, Kutbay Y, Arıkan Ş, Batum O, Kömürcuoğlu B, Ermin S. Clinical effects of T790M mutation in EGFR tyrosine kinase inhibitor resistant NSCLC patients. Kocaeli Med J 2021;10(2):51-56.

Abstract

INTRODUCTION: To compare patient characteristics between the T790M-positive and T790M-negative populations, and to analyze the post-progression survival (PPS) after initial tyrosine kinase inhibitor (TKI) failure in order to investigate the prognosis in patients undergoing rebiopsy.

METHODS: We investigated the patient characteristics, including the initial EGFR-TKI response and T790M status at the time of rebiopsy or liquid biopsy, subsequent treatment after resistance to the initial EGFR-TKI (the presence of EGFR-TKI re-challenge), treatment just before biopsy and/or rebiopsy (EGFR-TKIs or chemotherapy), the timing of the rebiopsy (just after the initial EGFR-TKI failure or others).

RESULTS: No difference was found between the two groups with T790M mutation positive and negative in terms of age, gender, and metastasis location. Only patients with positive T790M mutation had higher progression after TKI use compared to negative ones (p: 0.000). The progression-free median survival in patients using TKI was 19.33 months in the group with T790M mutation and 22.55 months in the negative group. Overall survival was found to be 75 months and 27.5 months in the T790M positive and negative group, respectively, and this was statistically significant. (p: 0.009).

DISCUSSION AND CONCLUSION: Overall survival was significantly longer in the T790M positive group than in the T790M negative group. In addition, liquid biopsy can be performed several times for patients with progression after EGFR-TKI use and who do not want to undergo tissue biopsy.

Keywords: liquid biopsy, lung cancer, survival, T790M mutation, tissue biopsy
INTRODUCTION

In recent years, significant advances have been made to treat patients with advanced lung cancer with targeted therapies and immune targeted therapy approaches. During systemic therapy, almost all tumors develop resistance to treatment due to tumor heterogeneity and clonal change. However, the emergence of the T790M resistance mutation during treatment constitutes most EGFR-TKI drug resistance. EGFR mutations are more frequently detected in never or light smokers, women, and adenocarcinomas. Exon 19 deletions and exon 21 L858R point mutations account for up to 90% of EGFR mutations (1-4).

First-generation EGFR tyrosine kinase inhibitors (TKIs) (i.e. erlotinib and gefitinib) are reversible EGFR inhibitors, whereas second-generation TKIs (i.e. afatinib), are irreversible pan-human epidermal growth factor receptor inhibitors that covalently bind to EGFR. Acquired resistance to EGFR TKIs causes disease progression after 9-15 months of TKI treatment (5-7). Several acquired resistance mechanisms were reported in the literature. The substitution of threonine to methionine at amino acid position 790 (T790M) in exon 20 of the EGFR gene decreases first- and second-generation EGFR TKI binding and enhancing the ATP binding affinity of EGFR-mutant receptor kinase domains in approximately 50% of resistant cases (8,10).

The traditional specimen taken for T790M mutation analysis is a tissue biopsy. However, in cases where the tissue sample can’t be reached or can’t be obtained due to patient-related reasons (biopsy rejection or unsuitable performance status), the liquid biopsy method is an alternative method that is less invasive and has rapid results. Liquid biopsies are used as to find T790M mutation in patients who have evidence for TKI resistance. However, due to 50% - 90% sensitivity of liquid biopsies depending on mutational analysis methods, when the result is negative, tissue biopsy is preferred (11,12). In addition, liquid biopsy based on the evaluation of genetic markers in blood for early diagnosis and follow-up of the disease is increasingly popular. Liquid biopsies can be helpful in genetic monitoring of the tumor, as the circulating free tumor DNA can represent the tumor genome. Also, liquid biopsy can be carried out many times, allowing molecular changes in tumor cells to be detected dynamically.

Clinical factors affecting acquired resistance mutation prevalence, particularly T790M, are still not clear. The purpose of the present study was to elucidate clinical factors related to the frequency of T790M mutations. We also planned this study for comparing various patient data between the T790M-positive and T790M-negative cases, and to analyze post-progression survival (PPS) after initial TKI failure in order to investigate the prognosis in patients undergoing a rebiopsy.

MATERIALS AND METHOD

Patients

Patients with EGFR-sensitive mutations who underwent a rebiopsy or liquid biopsy between 2015 and 2020 to confirm the emergence of T790M after EGFR-TKI became resistant, were retrospectively analyzed. Patient characteristics investigated included the initial EGFR-TKI response, T790M status during rebiopsy or liquid biopsy, following treatment after resistance to initial EGFR-TKIs (presence of EGFR-TKIs re-challenge), treatment before biopsy and/or rebiopsy (EGFR-TKIs or chemotherapy), and the timing of rebiopsy (following initial EGFR-TKIs failure).

A liquid biopsy was sent from all patients who were resistant to EGFR-TKI drugs. Tissue biopsies were performed from patients with a negative liquid biopsy result (Figure 1).

Here, post-progression survivals (PPS), are identified as the time from progressive disease to death from initial TKI therapy.

EGFR Mutation Analyses

Mutation analysis of exons 18–21 of EGFR was conducted with cycleave PCR (L858R point mutations in exon 21 (L858R) and T790M) and fragment analysis (deletions in exon 19 (Del19)).

Statistical Analysis

Statistical analysis was made through Sigma-Plot software with x2 test to correlate clinical data with T790M status, and Kaplan-Meier Estimator was also used to analyze median PFS and OS.

![Figure 1: Patient Disposition Chart](www.kocaelimj.org)
Table 1. Characteristics of Patients

|                          | n  | %   |
|--------------------------|----|-----|
| Gender                   |    |     |
| Male                     | 21 | 47.7|
| female                  | 23 | 52.3|
| Smoking history          |    |     |
| Ex-smoker                | 9  | 20.5|
| Nonsmoker                | 30 | 68.2|
| Smoker                   | 5  | 11.4|
| ECOG                     |    |     |
| 0                        | 17 | 38.6|
| 1                        | 23 | 52.3|
| 2                        | 3  | 6.8 |
| 3                        | 1  | 2.3 |
| Comorbid diseases        |    |     |
| Present                  | 11 | 25  |
| Absent                   | 33 | 75  |
| Stage (at diagnosis)     |    |     |
| Stage I                  | 1  | 2.3 |
| Stage IIIA               | 1  | 2.3 |
| Stage IIIB               | 4  | 9.1 |
| Stage IV                 | 38 | 86.4|
| Metastasis               |    |     |
| Present                  | 38 | 86.4|
| Absent                   | 6  | 13.6|
| Response to first line chemotherapy |    |     |
| Progression              | 17 | 38.6|
| Stable                   | 1  | 2.3 |
| Partial response         | 4  | 9.1 |
| Complete response        | 4  | 9.1 |
| EGFR mutation            |    |     |
| Positive                 | 43 | 97.7|
| Negative                 | 1  | 2.3 |
| 861Q                     | 1  | 2.3 |
| 858R                     | 14 | 31.8|
| EXON20                   | 2  | 4.5 |
| EXON19                   | 27 | 61.4|
| First line TKI           |    |     |
| Afatinib                 | 7  | 15.9|
| Gefitinib                | 6  | 13.6|
| Erlotinib                | 31 | 70.5|
| Progression during TKI   |    |     |
| Pulmonary and extrapulmonary | 15 | 34.1|
| Extrapulmonary           | 4  | 9.1 |
| Pulmonary                | 16 | 36.4|
| No progression           | 9  | 20.5|
| T790M                    |    |     |
| Positive                 | 24 | 54.5|
| Negative                 | 20 | 45.5|

ECOG: Eastern Cooperative Oncology Group
TKI: tyrosine kinase inhibitor

Table 2. Relationship between Clinical Features According to the T790M Mutation

|                          | T790M positive | T790M negative | p   |
|--------------------------|----------------|----------------|-----|
| Age                      | 62.5±12.7      | 62.6±11.5      | 0.944|
| Male                     | 12 (50%)       | 9 (45%)        | 0.975|
| Female                   | 12 (50%)       | 11 (55%)       |     |
| Comorbid diseases        | 1.000          |                |     |
| Present                  | 6 (25%)        | 5 (25%)        |     |
| absent                   | 18 (75%)       | 15 (75%)       |     |
| Metastasis               |                |                |     |
| Present                  | 21 (87.5%)     | 17 (85%)       | 1.000|
| absent                   | 3 (12.5%)      | 3 (15%)        |     |
| Progression after TKI use| 24 (100%)      | 11 (55%)       | 0.000|
| Present                  | 0              | 9 (45%)        |     |
| absent                   |                |                |     |
| Survival                 |                |                |     |
| Exitus                   | 8 (33.3%)      | 13 (65%)       | 0.073|
| Alive                    | 16 (66.7%)     | 7 (35%)        |     |

TKI: tyrosine kinase inhibitor

Table 2 is shown in result section.

RESULTS

Gefitinib (N: 6; 13.6%), erlotinib (N: 31; 70.5%) or afatinib (N: 7; 15.9%) were used for forty-four patients as first-line treatment. Liquid biopsies were sent from all patients. Tissue biopsies were performed from those whose liquid biopsy result was negative. Both tissue and liquid biopsies were sent from 30 patients. For 10 patients, the tissue biopsy was positive as well as the liquid biopsy being negative. In 20 patients, both tissue and liquid biopsy were negative. The liquid biopsies of 14 patients were found to be positive. The characteristics of patients are shown in Table 1.

No difference was found between the two groups with positive and negative T790M mutations in terms of age, gender and metastasis location (Table 2).

Only patients with a positive T790M mutation had higher progression after TKI use compared to patients with a negative mutation (p: 0.000). The progression-free median survival in patients using TKI was 19.33 months in the group with a T790M mutation, and 22.25 months in the negative group (Figure 2). Overall survival was 75 months and 27.5 months, respectively, in the T790M positive and negative group and this was statistically significant (p: 0.009) (Figure 3).
DISCUSSION

Evidence on clinical characteristics of cases who have EGFR mutations potentially estimating the acquisition of T790M mutation is currently limited, and is conducted only with Asian cases (13-20). In our study, no difference was found between the two groups of T790M mutation positive and negative, in terms of clinical features. Previous studies examined age as a clinical factor correlated with T790M mutation, but without any important results in most patients (15). However, a Japanese case series reported positive correlations in cases that were older than 75 years, but the median age was older than our series (19). In another study cases younger than 65 with exon 19 deletion as baseline sensitizing mutation were found to be correlated with acquired T790M mutation at disease progression (20). The low number of patients in our study and the low number of patients over the age of 65 may be the reason why no difference was found.

In this study, the prevalence of acquired T790M mutations was evaluated simultaneously in 44 patients with biopsy and plasma specimens. Both tissue and liquid biopsies were collected from 30 patients. Tissue biopsies of 10 patients were positive whereas their liquid biopsies were negative. In 20 patients, both tissue and liquid biopsy were negative. Liquid biopsies of 14 patients were found to be positive. Since liquid biopsies were noninvasive, tissue biopsies were performed on those whose liquid biopsy results were negative. Positive results in 14 of the 44 patients indicated a high rate. For this reason, it would be more appropriate to conduct and evaluate liquid biopsies first, which is a less invasive method. Thress et al. reported the positivity rate of simultaneous measurements of tissue specimens and plasma specimens as 81% and 58%, respectively (21). Other researchers have found that the positivity rate of acquired T790M mutations in plasma specimens was approximately 40% (22, 23). Jenkins et al. reported that plasma testing did not detect the T790M mutation in plasma-circulating tumor DNA of ca. 40% of patients who had T790M-positive tissue testing results (24). Even in two patients, it was seen that the first liquid biopsy was negative, and then the second liquid biopsy sent 3 months later was positive. Of course, patients cannot wait for the second liquid biopsy and it will be more accurate to send tissue biopsies during this period. However, it may be appropriate to send a liquid biopsy from time-to-time in patients who are also negative in tissue biopsies, because tissue biopsies are an invasive method. Alternatively, if the patient does not want to have a tissue biopsy with an invasive method again, we think that several liquid biopsies can be sent from the patient.

The T790M mutation was detected in our study after afatinib, erlotinib and gefitinib treatment. After erlotinib treatment, the T790M mutation was detected in 16 patients and it was found in four patients who received afatinib and gefitinib treatment. One study from Kyushu University reported the results of 37 patients across 13 institutes who acquired T790M mutations upon recurrence after the administration of afatinib were found in 43.2% of patients with EGFR mutations (25). In another study, the rate of acquired T790M mutations was similar in any combination of EGFR-TKI (19).

In our study, patients with a positive T790M mutation had higher progression after TKI use compared to patients with a negative mutation. While progression was observed in all patients with positive T790m mutation in patients using TKI, progression was observed in 11 (55%) of the patients without T790M mutation, which was statistically significant. It was argued in a trend that was not statistically significant that there was a higher prevalence of T790M mutation in patients with better and longer response to previous EGFR TKIs, which is in agreement with the data reported for a smaller Japanese series (17).

It is recommended in European Guidelines that tissue or liquid biopsies are performed for disease progression (26); however, the accurate time for cf-DNA analysis and liquid rebiopsy for initial negativity was not elucidated.

However, previous data of a Caucasian cohort revealed that T790M was more prevalent in lung/pleura tissue, and lymph node
biopsies compared to more distant areas (48). A likely explanation argues that tumor heterogeneity of metastatic areas affects tissue biopsy when compared with liquid biopsy. They also conducted liquid/tissue biopsy according to instructions for clinical practice, and not for prospective biopsy protocol, in which the time point of specimen collection was pre-defined (27). In our study, although progression was detected less in extrapulmonary organs, it was generally preferred to take a tissue biopsy from the lung, where it is more common.

Finally, we also analyzed the survival data of the patients and found that the progression-free median survival in patients using TKI was 19.33 months in the group with T790M mutation and 22.25 months in the negative group. Overall survival was 75 months and 27.5 months, respectively, in the T790M positive and negative groups, which was statistically significant. In another study, it was reported that there was a median OS of 52.8 months in T790M patients (vs. 25 months in without T790M patients); all of whom received second-line osimertinib treatment; this might explain survival benefits (20). In another study (17), the PPS and OS in patients with EGFR T790M positive (N = 21) who received osimertinib were longer at significant levels compared to those who were T790M-negative (N = 87), and those with EGFR-positive T790M without other 3G-EGFR-TKI treatment. The study also found longer durations for PFS at initial treatment with EGFR-TKIs, which was associated with T790M mutation at significant levels. They also found that patients who with T790M mutation after initial EGFR-TKIs resistance might have longer PFS when compared to those without T790M mutation (17).

There were several limitations in our study. Firstly, the data were collected retrospectively from one single institution, and the sampling size was small, the timing of biopsy varied in patients, and was not consistent (as expected in a prospective study). Secondly, the T790M status was analyzed only in rebiopsy areas and not in the entire tumor. In an individual patient, T790M mutation status was reported as spatiotemporally heterogeneous because of selective pressure of EGFR-TKIs (28). There were no patients undergoing rebiopsy for brain or bone progression lesions. Subsequently, rebiopsy areas might have caused biased detection of T790M mutation. In addition, waiting for the results of the liquid biopsy, which is a more non-invasive examination at first, and sending the patient to tissue biopsy also causes a waste of time.

In conclusion, this study conducted in the Turkish population found that the survival time was longer in the T790M positive group compared to the T790M negative group, that was statistically significant. In addition, it was also found that a liquid biopsy could be sent several times in patients who do not want to have a tissue biopsy, especially in patients with progression of EGFR-TKI drugs who do not want to undergo a tissue biopsy.

Ethics Committee Approval: This is a retrospective study, local ethical approval was received and ethical approval date and number 28.02.2020-3. The study protocol was approved by the

Izmir Dr. Suat Seren of the Chest Diseases and Surgery Training Hospital.

Conflict of Interest: The author declare there are no potential conflicts of interest. This article is protected by copyright. All rights reserved.

Funding: The authors declare there is no financial support for this study.

Informed Consent: Informed consent was waived because of the retrospective nature of the study.

REFERENCES

1. Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sruanpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonsmall-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29: 2866-74. https://doi.org/10.1200/JCO.2010.33.4235

2. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361: 958-67. https://doi.org/10.1056/NEJMoa0904554

3. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-57. https://doi.org/10.1056/NEJMoa0810699

4. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97: 339-46. https://doi.org/10.1093/jnci/dji055

5. Wu Y-L, Zhou C, Hu C-P, Feng J, Lu S, Huang Y, et al. Afinatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 213-22. https://doi.org/10.1016/S1470-2045(13)70604-1

6. Jackman D, Pao W, Riely GJ, Kris MG, Jänne PA, Lynch T, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer. J Clin Oncol. 2010; 28: 357-60. https://doi.org/10.1200/JCO.2009.24.7049

7. Park K, Tan E-H, O’Byrne K, Zhang L, Boyer M, Moket T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17: 577-89. https://doi.org/10.1016/S1470-2045(16)30033-X

8. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, TurkeAB, Fidias P, et al. Genotypic and histologicevolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3: 75ra26. https://doi.org/10.1126/scitranslmed.3002003
9. Yun C-H, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105: 2070-5. https://doi.org/10.1073/pnas.0709662105

10. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19: 2240-7 https://doi.org/10.1158/1078-0432.CCR-12-2246

11. Sacher AG, Komatsubara KM, Oxnard GR. Application of plasma genotyping technologies in nonesmall cell lung cancer: a practical review. J Thorac Oncol. 2017; 12: 1344-56. https://doi.org/10.1016/j.jtho.2017.05.022

12. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement from the IASLC. J Thorac Oncol. 2018; 13: 1248-68. https://doi.org/10.1016/j.jtho.2018.05.030

13. Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. Cancer. 2013; 119: 4325-32. https://doi.org/10.1002/cncr.28364

14. Ji W, Choi CM, Rho JK, Jang SJ, Park YS, Chun S-M, et al. Mechanisms of acquired resistance to EGFRtyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer. 2013; 13: 606. https://doi.org/10.1186/1471-2407-13-606

15. Tseng JS, Su KY, Yang TY, Chen K-C, Hsu K-H, Chen H-Y et al. The emergence of T790M mutation in EGFRmutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M. Oncotarget. 2016; 7: 48059-69. https://doi.org/10.18632/oncotarget.10351

16. Nosaki K, Satouchi M, Kurata T, Yoshida T, Okamoto I, Katakami N, et al. Re-biopsy status among non-small cell lung cancer patients in Japan: a retrospective study. Lung Cancer. 2016; 101: 1-8. https://doi.org/10.1016/j.lungcan.2016.07.007

17. Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, et al. Association between EGFR T790M status and progression patterns during initial EGFR-TKI treatment in patients harboring EGFR mutation. Clin Lung Cancer 2017; 18: 698-705.e2. https://doi.org/10.1016/j.clcc.2017.05.004

18. Ke EE, Zhou Q, Zhang QY, Su J, Chen Z-H, Zhang X-C, et al. A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R. J Thorac Oncol. 2017; 12: 1368-75. https://doi.org/10.1016/j.jtho.2017.05.018

19. Kaburagi T, Kiyoshima M, Nawa T, Ichimura H, Saito T, Hayashihara K, et al. Acquired EGFR T790M mutation after relapse following EGFR-TKI therapy: a population-based multi-institutional study. Anticancer Res. 2018; 38: 3145-50. https://doi.org/10.21873/anticanres.12577

20. MasoAD, Lorenzi M, Roca E, Pilo SST, Macerelli M, Polo V, et al. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Nonesmall-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer. 2020; 21(1): 1-14.e3. https://doi.org/10.1016/j.jlcc.2019.07.009

21. Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: A crossplatform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015; 90: 509-515. https://doi.org/10.1016/j.lungcan.2015.10.004

22. Sueoka-Aragane N, Katakami N, Satouchi M, Yokota S, Aoe K, Iwanaga K, et al. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci. 2016; 107: 162-167. https://doi.org/10.1111/cas.12847

23. Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016; 6: 20913. https://doi.org/10.1038/srep20913

24. Jenkins S, Yang J-C, Ramalingam S, Yu K, Patel S, Weston S, et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2017; 12: 1061-1070. https://doi.org/10.1016/j.jtho.2017.04.003

25. Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, et al. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget. 2017; 8: 68123-68130. https://doi.org/10.18632/oncotarget.19243

26. Planchar D, Popat S, Kerr K, Novello S, Smit EF, Fairve-Finn, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv192-237. https://doi.org/10.1093/annonc/mdy275

27. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011; 17:1616-22 https://doi.org/10.1158/1078-0432.CCR-10-2692

28. Hata A, Katakami N, Yoshioka H, Kaji R, Masago K, Fujita S, et al. Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol. 2014; 9(8): 64-5. https://doi.org/10.1097/JTO.0000000000000255